伊达比星、阿糖胞苷和克拉屈滨诱导急性髓系白血病

Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.

作者信息

Wiedower Eric, Jamy Omer, Martin Michael G

机构信息

Department of Hematology/Oncology, The West Clinic, Memphis, TN, U.S.A.

Department of Internal Medicine, The University of Tennessee Health Science Center, Memphis, TN, U.S.A.

出版信息

Anticancer Res. 2015 Nov;35(11):6287-90.

PMID:26504064

Abstract

BACKGROUND

Daunorubicin and cytarabine has been the standard-of-care for induction therapy for acute myeloid leukemia (AML). Adding cladribine to daunorubicin (60 mg/m(2)) and cytarabine has increased complete remission (CR) rates and median overall survival (OS). However, the efficacy of adding cladribine to 7+3 with other anthracyclines is unknown.

PATIENTS AND METHODS

We retrospectively evaluated patients with AML receiving induction with idarubicin, cytarabine and cladribine (ICC) between 1/1/2010 and 06/30/2015 at the Methodist University Hospital in Memphis, Tennessee. Institutional Review Board approval was obtained for the study. Patient, disease characteristics and outcomes were analyzed with GraphPad Prism, Microsoft Excel and SPSSv19.0 software.

RESULTS

Twenty-four patients induced with ICC for AML were identified. Thirteen (54.2%) had at least one high-risk feature. Hypoplastic marrow was achieved in all by day 14; 19 (79.2%) achieved CR. Thirty-day mortality was 8.3%; 33-month OS and disease-free survival were 56% and 36%, respectively.

CONCLUSION

Induction of AML with ICC was associated with a high CR rate and OS in our high-risk population.

摘要

背景

柔红霉素和阿糖胞苷一直是急性髓系白血病（AML）诱导治疗的标准疗法。在柔红霉素（60mg/m²）和阿糖胞苷基础上加用克拉屈滨可提高完全缓解（CR）率和中位总生存期（OS）。然而，在7+3方案中加入克拉屈滨联合其他蒽环类药物的疗效尚不清楚。

患者与方法

我们回顾性评估了2010年1月1日至2015年6月30日期间在田纳西州孟菲斯卫理公会大学医院接受伊达比星、阿糖胞苷和克拉屈滨（ICC）诱导治疗的AML患者。该研究获得了机构审查委员会的批准。使用GraphPad Prism、Microsoft Excel和SPSSv19.0软件分析患者、疾病特征和结局。